These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21188109)

  • 1. Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
    Galimberti S; Petrini M
    Cancer Manag Res; 2010 Jun; 2():181-9. PubMed ID: 21188109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
    Coiffier B
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.
    Hoy SM; McKeage K
    Drugs; 2010 Oct; 70(14):1819-29. PubMed ID: 20836575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis.
    Hess G; Coiffier B; Crump M; Gisselbrecht C; Offner F; Romaguera J; Kang L; Moran PJ
    Exp Hematol Oncol; 2015; 4():11. PubMed ID: 25938001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
    Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
    Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
    Coiffier B; Ribrag V
    Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.
    Samad N; Younes A
    Onco Targets Ther; 2010 Sep; 3():167-78. PubMed ID: 20856791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
    Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
    Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
    Yazbeck VY; Buglio D; Georgakis GV; Li Y; Iwado E; Romaguera JE; Kondo S; Younes A
    Exp Hematol; 2008 Apr; 36(4):443-50. PubMed ID: 18343280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
    Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
    Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
    Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
    Wang L; Shi WY; Wu ZY; Varna M; Wang AH; Zhou L; Chen L; Shen ZX; Lu H; Zhao WL; Janin A
    J Hematol Oncol; 2010 Sep; 3():30. PubMed ID: 20828385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus.
    Schulze M; Stock C; Zaccagnini M; Teber D; Rassweiler JJ
    Recent Results Cancer Res; 2014; 201():393-403. PubMed ID: 24756806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus for the treatment of mantle cell lymphoma.
    Hess G
    Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.